BRCA Biomarkers News and reporting on BRCA biomarkers. Dec 12, 2022 Ideaya Biosciences Files IND With FDA for PARG Inhibitor Nov 8, 2022 Tests to Guide PARP Inhibitors Emerge as New Focus for Public-Private Harmonization Effort Premium Nov 1, 2022 Myriad Genetics to Submit Hereditary Cancer Risk Variants to ClinVar in 2023 Premium Oct 3, 2022 Clovis Oncology to File sNDA for Rubraca in BRCA1/2-Mutant Prostate Cancer Sep 26, 2022 WEHI Launches Project to Improve Genomic Data Interpretation, Precision Cancer Care in Australia Sep 21, 2022 Merck KGaA, Nerviano Enter License Agreement for PARP1 Inhibitor NMS-293 Sep 13, 2022 Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response Sep 10, 2022 Lynparza Presents Possibility of Cure for Some Patients With Biomarker-Defined Ovarian Cancer Premium Sep 6, 2022 UK's MHRA Approves Adjuvant Lynparza for BRCA-Mutant, High-Risk Early Breast Cancer Aug 29, 2022 Ideaya Reaches Milestone in Deal With GSK for Pol Theta Helicase Program Aug 26, 2022 Myriad Genetics Gets Expanded Coverage for BRACAnalysis CDx in Japan Aug 25, 2022 AstraZeneca's Tagrisso, Lynparza Net Adjuvant Approvals in Japan Aug 18, 2022 Dana-Farber Educating Black, Latinx Patients Hoping to Boost Pancreatic Cancer Genetic Risk Testing Premium Aug 17, 2022 Oncologists Consider Germline Testing in Lung Cancer Patients Amid New Data Showing High Prevalence Premium Aug 4, 2022 Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jul 25, 2022 EMA's CHMP Recommends Restricting Third-Line Ovarian Cancer Indication for Clovis' Rubraca Jul 13, 2022 Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients Jul 7, 2022 Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response Jul 6, 2022 Zenith Epigenetics to Explore BET Inhibitor Combinations in Multiple NCI-Sponsored Trials Load More Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
